{"id":"NCT00803595","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"A Multinational Phase III Study of CS-8958 (MARVEL)","officialTitle":"A Randomized Double-blind Controlled Study of CS-8958 Versus Oseltamivir Phosphate in Patients With Influenza Virus Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2009-03","completion":"2009-06","firstPosted":"2008-12-05","resultsPosted":"2011-11-22","lastUpdate":"2019-01-09"},"enrollment":1002,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Influenza, Human"],"interventions":[{"type":"DRUG","name":"CS-8958","otherNames":[]},{"type":"DRUG","name":"CS-8958","otherNames":[]},{"type":"DRUG","name":"oseltamivir phosphate","otherNames":[]}],"arms":[{"label":"CS-8958 Low Dose","type":"EXPERIMENTAL"},{"label":"CS-8958 High Dose","type":"EXPERIMENTAL"},{"label":"Oseltamivir phosphate","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to confirm the efficacy of CS-8958 administered as a single inhaled low dose or single inhaled high dose by showing non-inferiority to oseltamivir phosphate using the time to alleviation of influenza illness. For safety evaluation, between-group comparisons will be made with regard to incidence of adverse events and other safety measures.\n\nIn a secondary objective, the optimum dosage of CS-8958 for this indication will be evaluated based on the efficacy and safety of single inhaled low or high dose.","primaryOutcome":{"measure":"Time to Alleviation of Influenza Illness","timeFrame":"15 days","effectByArm":[{"arm":"CS-8958 High Dose 40 mg","deltaMin":73,"sd":null},{"arm":"CS-8958 Low Dose 20 mg","deltaMin":85.8,"sd":null},{"arm":"Oseltamivir 75 mg","deltaMin":73.6,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"0.748"},{"comp":"OG000 vs OG001","p":"0.038"},{"comp":"OG001 vs OG002","p":"0.104"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":4,"countries":["China","Japan","South Korea","Taiwan"]},"refs":{"pmids":["20936975"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":337},"commonTop":["Diarrhoea","Nasopharyngitis","Nausea","Alanine aminotransferase increase","Vomiting"]}}